Contact this trialFirst, we need to learn more about you.
Glucagon-like peptide-1 receptor agonist
Semaglutide for Obesity
Recruiting1 awardPhase 3
Skokie, Illinois
This trial is testing whether the drug semaglutide can reduce the risk of cardiovascular events (like heart attacks or strokes) in people who are overweight or obese and have already had one such event. People taking part will be randomly assigned to either take semaglutide or a placebo (dummy) drug, and neither they nor the researchers will know who is taking which. The trial will last for 2.5 to 5 years, with participants making up to 25 visits to the study doctor.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.